BRPI0612471A2 - novos compostos como agonistas glp-1 - Google Patents

novos compostos como agonistas glp-1

Info

Publication number
BRPI0612471A2
BRPI0612471A2 BRPI0612471A BRPI0612471A BRPI0612471A2 BR PI0612471 A2 BRPI0612471 A2 BR PI0612471A2 BR PI0612471 A BRPI0612471 A BR PI0612471A BR PI0612471 A BRPI0612471 A BR PI0612471A BR PI0612471 A2 BRPI0612471 A2 BR PI0612471A2
Authority
BR
Brazil
Prior art keywords
glp
agonists
new compounds
compounds
new
Prior art date
Application number
BRPI0612471A
Other languages
English (en)
Inventor
Braj Bhushan Lohray
Rajesh H Bahekar
Vidya Bhushan Lohray
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of BRPI0612471A2 publication Critical patent/BRPI0612471A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0612471A 2005-05-05 2006-05-04 novos compostos como agonistas glp-1 BRPI0612471A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN558MU2005 2005-05-05
IN645MU2005 2005-05-31
PCT/IN2006/000154 WO2007017892A2 (en) 2005-05-05 2006-05-04 Novel compounds as glp-i agonists

Publications (1)

Publication Number Publication Date
BRPI0612471A2 true BRPI0612471A2 (pt) 2016-09-06

Family

ID=37727716

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0612471A BRPI0612471A2 (pt) 2005-05-05 2006-05-04 novos compostos como agonistas glp-1

Country Status (12)

Country Link
EP (1) EP1891106A2 (pt)
JP (1) JP2008540402A (pt)
KR (1) KR20080021636A (pt)
AP (1) AP2007004227A0 (pt)
AU (1) AU2006277557A1 (pt)
BR (1) BRPI0612471A2 (pt)
CA (1) CA2606894A1 (pt)
EA (1) EA200702419A1 (pt)
IL (1) IL187105A0 (pt)
MX (1) MX2007013655A (pt)
NO (1) NO20075618L (pt)
WO (1) WO2007017892A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
CA2665033C (en) * 2006-10-03 2013-10-01 Cadila Healthcare Limited Antidiabetic compounds
CA2707448C (en) 2007-12-11 2014-10-14 Cadila Healthcare Limited Peptidomimetics with glucagon antagonistic and glp-1 agonistic activities
EP2222695A2 (en) * 2007-12-11 2010-09-01 F. Hoffmann-La Roche AG Insulinotropic peptide synthesis using solid and solution phase combination techniques
CN102414220A (zh) * 2009-05-01 2012-04-11 霍夫曼-拉罗奇有限公司 使用固相和液相组合技术的促胰岛素肽合成
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
US9938334B2 (en) 2013-02-15 2018-04-10 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
GB0024428D0 (en) * 2000-10-05 2000-11-22 King S College Absorption enhancers
CA2455963C (en) * 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MXPA04006679A (es) * 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
BRPI0507594A (pt) * 2004-02-11 2007-07-03 Amylin Pharmaceuticals Inc polipetìdeos hìbridos com propriedades selecionáveis
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin

Also Published As

Publication number Publication date
MX2007013655A (es) 2008-01-24
WO2007017892A2 (en) 2007-02-15
IL187105A0 (en) 2008-02-09
EA200702419A1 (ru) 2008-04-28
JP2008540402A (ja) 2008-11-20
WO2007017892A3 (en) 2007-09-20
AU2006277557A1 (en) 2007-02-15
AP2007004227A0 (en) 2007-12-31
KR20080021636A (ko) 2008-03-07
NO20075618L (no) 2008-01-30
CA2606894A1 (en) 2007-02-15
EP1891106A2 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
LTC2004635I2 (lt) Pakeistieji enaminokarbonilo junginiai
FR18C1017I2 (fr) Composes de glp-1 acyles
BRPI0718266A2 (pt) Compostos heterocíclicos como agentes anti-inflamatórios.
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
BRPI0810250A2 (pt) Compostos inéditos
CY2013047I2 (el) Ενωσεις διαρυλυδαντοϊνης
EP2044055A4 (en) amide compounds
DK2185567T3 (da) Substituerede bicyclolactam-forbindelser
BRPI0718874A2 (pt) Compostos orgânicos
NO20084803L (no) organiske forbindelser
BRPI0718478A2 (pt) Compostos orgânicos
NO20082030L (no) Styrt voltametri
CR10049A (es) Derivados de tiadiazol como agentes antidiabéticos
BRPI0813500A2 (pt) Compostos antivirais
ATE524477T1 (de) Aziridinylepothilonverbindungen
CR10353A (es) Nuevos compuestos.
BRPI0712902A2 (pt) compostos orgânicos
BRPI0811264A2 (pt) Compostos
BRPI0718494A2 (pt) Derivado de fenilsulfamoil benzamida como antagonistas de bradicinina
NO20055686D0 (no) Sammensetning
BRPI0809996A2 (pt) Compostos
DE602006018127D1 (de) Acetylenderivate
DK1937650T3 (da) Heterocykliske forbindelser
ATE443056T1 (de) Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
EP1960358A4 (en) ANTINEOPLASTIC COMPOUNDS

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B11Z Dismissal: petition dismissal - article 216, par 2 of industrial property law

Free format text: REFERENTE A PETICAO NO 18070073380/SP DE 05/11/2007.

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: O DESPACHO6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B11M Decision cancelled [chapter 11.13 patent gazette]

Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]